Back to News
Market Impact: 0.4
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals

Phase 3 Aspire failed to achieve the primary endpoint, showing no significant change from baseline in Bayley-4 cognitive raw score. The trial also missed the key secondary endpoint, net response in the Multidomain Responder Index (MDRI), increasing clinical and regulatory uncertainty around the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Why Viking Therapeutics Stock Skyrocketed on Tuesday
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- This AI-picked miner jumps 14.5% as a $120M copper deal lands
- Heidi CEO on AI in Healthcare, $900M valuation
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder